Figure 5
Analysis of the mAb interaction with the PrG-SWCNT/ Gra complexes. (A) The Bradford protein assay results of content of the mAb loaded on the PrG-SWCNT and the PrG-Gra complex. All p values were &p < 0.01 except the one which was highlighted in the figure. (B) The ELISA assay for determination of the Anti-IgGk-HRP sensitivity for the mAb kappa light chain in presence of the PrG. (C) Analysis of the mAb interaction with the PrG-SWCNT/Gra and (D) Calorimetric assay at 450 nm was used to define the loading content of the mAb in presence of the PrG-SWCNT/Gra complex with Anti-IgGk-HRP. The ELISA assay for determination of amount of mAb adsorbed or well-oriented to the PS and several modified PS, including (1) PS, (2) PS-mAb (5 µg/ml), (3) PS-mAb (10 µg/ml), (4) PS-mAb (15 µg/ml), (5) PS-PrG-mAb (5 µg/ml), (6) PS-PrG-mAb (10 µg/ml), (7) PS-PrG-mAb (15 µg/ml), (8) PS- SWCNT-PrG-mAb (5 µg/ml), (9) PS-SWCNT-PrG-mAb (10 µg/ml), (10) PS-SWCNT-PrG-mAb (15 µg/ml), (11) PS-Gra-PrG-mAb (5 µg/ml) (12), PS-Gra-PrG-mAb (10 µg/ml), PS-Gra-PrG-mAb (15 µg/ml). Data are expressed as mean ± STD with n = 3. *p < 0.001; &p < 0.01; and #p < 0.05. UV-Visible spetra of (F) the PrG-SWCNT and (G) the PrG-Gra incubated with the three differents concentration of the mAb.
